ACC 2023: Late-Breaking Science Video Collection
Published: 06 March 2023
-
Views:
3058
-
Likes:
7
-
Views:
3058
-
Likes:
7
-
Up Next -
17m 32s -
12m 7sPart 1 | Session 5 The BIOVASC Trial with Dr Harriette Van Spall & Prof Roberto Diletti
-
05:59Part 2 | Session 1 Statins to Protect Heart During Cancer Treatment: The STOP-CA Trial -
5m 38sPart 2 | Session 2 RENOVATE-COMPLEX-PCI: IVUS Vs OCT Optimisation in Complex PCI -
8m 1sPart 2 | Session 3 Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study -
5m 41s -
3m 46s -
5m 53s -
3m 44sPart 2 | Session 7 MK-0616: Oral PCSK9 inhibitor In Hypercholesterolemia Patients -
5m 20sPart 2 | Session 8 Evaluation of the Mechanism of Benefit for Dapagliflozin in HFpEF -
3m 7sPart 2 | Session 9 BMAD Trial: μCor in Ambulatory Decompensated Heart Failure -
-
33m 28sPart 3 | Session 1 ACC.23 Late-breaking Science Wrap Up -
22:04Part 3 | Session 2 What's Hot at ACC.23? Late-breaking Science Preview
-
16m 22s -
5m 34sPart 4 | Session 2 Lipid Management & the CLEAR Trial with Dr Erin Michos -
Part 4 | Session 3 Obesity Management Strategies in 2023 with Dr Harold Bays -
15m 9sPart 4 | Session 4 ACC.23 President Interview with Dr B Hadley Wilson
-
16:12Part 1 | Session 1 The CLEAR-Outcomes Trial with Dr Harriette Van Spall & Dr Steven Nissen Harriette Van Spall, Steven E Nissen
-
16:24Part 1 | Session 2 The REVIVED-BCIS2 Viability Study with Dr Harriette Van Spall, Dr Divaka Perera & Dr Peter O'Kane Harriette Van Spall, Divaka Perera, Peter O’Kane
Overview
Our regular review series View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provides a critical analysis of the late-breaking and featured science results and spotlights impactful data.
For a deeper look into the key clinical trial data revealed at ACC 23, Dr Harriette Van Spall (McMaster University, Hamilton, CA) interviews the principal investigators in her regular Late-Breaker Discussion Series.
For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research.
More from this programme
Part 1
Late-Breaker Discussion Series
Host, Dr Harriette Van Spall is joined by principle investigators for discussion on selected late-breaking trials.
Part 2
Expert Interviews
Part 3
View from the Thoraxcenter
In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at ACC 2023.
Part 4
Highlights Reviews
About the episode
ACC.23/WCC — Join Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) and investigator, Dr Amrita Mukhopadhyay (NYU School of Medicine, US) in their engaging discussion on the BETTER CARE-HF trial.
The BETTER CARE-HF trial investigated the effectiveness of two electronic clinical decision support (CDS) tools to support prescribing proven therapies for heart failure with reduced ejection fraction (HFrEF).
The trial developed two targeted CDS tools and compared their effectiveness against usual care on the primary outcome of MRA prescribing. The trial included 1,859 patients who were randomized across >50 practices and 180 cardiologists. BETTER CARE-HF is the first study to directly compare the effectiveness of an alert and message to improve prescribing.
Recorded remotely from Hamilton and New York, 2023.
Faculty Biographies
Harriette Van Spall
Associate Professor of Medicine, Director of E-Health and Virtual Care
Dr Harriette Van Spall is an Associate Professor of Medicine and cardiologist and serves as Director of E-Health at McMaster University, Canada. She completed her medical and postgraduate clinical training at the University of Toronto and earned a Master of Public Health degree at Harvard University, US. Dr Van Spall is a Canadian Institutes of Health Research-funded clinical trialist and researcher with a focus on heart failure, health services, and health disparities.
She has garnered more than $4 million in research funding, has won several research awards, and has published her work in high-impact medical journals. She is an invited speaker, media correspondent, and editorial board member active in peer review at several high-impact medications journals and grant funding agencies, including Canadian Institutes of Health Research and Heart and Stroke Foundation of Canada.
Dr Van Spall is an Editorial Board…
Comments